A dry-pow­der lung dis­ease drug and next-gen an­tibi­otics: Two biotechs and an $880M slate of SPACs land on Wall Street with big ideas

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

An­oth­er cou­ple of biotech com­pa­nies and four SPACs are hit­ting Wall Street, adding to yet an­oth­er busy week for IPOs.

Aerovate Ther­a­peu­tics is tak­ing its dry-pow­der ver­sion of a pop­u­lar can­cer drug pub­lic, rak­ing in more than $121 mil­lion. Acurx Phar­ma­ceu­ti­cals snared a mod­est $14.8 mil­lion raise to tack­le the loom­ing threat of an­timi­cro­bial re­sis­tance. And Chamath Pal­i­hapi­tiya, the so-called ‘SPAC King,’ has round­ed up $880 mil­lion across four blank check com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER